Chloroquine modulation of specific metabolizing enzymes activities: Investigation with selective five drug cocktail

British Journal of Clinical Pharmacology

Volumn 46, Issue 3, 1998, Pages 215-219

  Adedoyin, Adedayo ^a   Frye, Reginald F ^a   Mauro, Kelly ^a   Branch, Robert A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Chloroquine; Drug cocktail; Inhbition; Metabolism; Selective inhibition

Indexed keywords

CAFFEINE; CHLOROQUINE; CHLORZOXAZONE; CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DRUG METABOLIZING ENZYME; MEPHENYTOIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; MODULATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ANTIMALARIALS; CAFFEINE; CHLOROQUINE; CHLORZOXAZONE; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; DEBRISOQUIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; ISOENZYMES; MALE; PHENOTYPE;

EID: 0031688229     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00765.x     Document Type: Article

References (28)

1. Slater AFG. Chloroquine: mechanism of drug action and resistance in Plasinodiuin falcipaniin. Phannac Tlier 1993; 57; 203-235.
2. Titus EO. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Tlier Dmg Monit 1989; 11: 369-379.
3. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Phannaeola'n 1985; 10: 187-215.
4. Wolheim FA, Hanson A, Laurell C-B. Chloroquine treatment in rheumatoid arthritis. Scand J Rlienmatol 1978; 7: 171-176.
5. Rothfield N. Efficacy of antimalarmls in systemic lupus erythematosus. Am] Med 1988; 85: 53-56.
6. Laaksonen A-L, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 1974; 3: 103-108.
7. Blazar BR, Whitley CB, Kitabchi AE, et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 1984; 33: 1133-1137.
8. Smith GD, Amos TAS, Mahler R, Peters TJ. Effect of chloroquine on insulin and glucose homeostasis in normal . subjects and patients with non-insulin-dependent diabetes mellitus. BrMedJ 1987; 294: 465-467.
9. Lancaster DL, Adio RA, Tai KK, et al Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.JP/Mmi Pliarmacol 1990; 42: 267-271.
10. Emerole GO, Thabrew MI. Changes in some rat hepatic microsomal components induced by prolonged administration of chloroquine. Kochern Pliarmacol 1983; 32: 3005-3009.
11. Nwankwo JO, Garba MA, Chinje CE, Mgbojikwe LO, Emerole GO. Possible chloroquine-induced modification of N-acetylation of isoniazid and sulphadimidine in the rat. Biochem Phannacol 1990; 40: 654-659.
12. Cotton DWK, Sutorius AHM. Inhibiting effect of some antimalarial substances on glucose-6-phosphate dehydrogenase. Mature 1971; 233: 197.
13. Roskoski, Jr. R, Jaskunas SR. Chloroquine and primaquine inhibition of rat liver cell-free polynucleotide-dependent polypeptide synthesis. Biochem Phannacol 1972; 21: 391-399.
14. Lefler CF, Lilja HS, Holbrook, Jr. DJ. Inhibition of aminoacylation and polypeptide synthesis by chloroquine and primaquine in rat liver in vitro. Biochem Phannacol 1973; 22: 715-728.
15. Masimirembwa CM, Gustafsson LL, Dahl M-L, Abdi YA, Hasler JA. Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes. BrJ Clin Phannacol 1996; 41: 344-346.
16. Back DJ, Riviere JH. Inhibition of hepatic drug metabolism by quinoline derivatives in vitro. BrJ Pliarmacol 1986; 86: 801P.
17. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogcnetics 1994; 4: 109-116.
18. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
19. Eichelbaum M, Bertilsson L, SäweJ, Zekorn C. Polymorphic oxidation of spartcine and debrisoquine: related pharmacogenctic entities. Clin Phannacol Tlier 1982; 31: 184-186.
20. Kharasch ED, Thummel KE, MhyreJ, Lillibridge JH. Singledose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pliarmacol Tlier 1993; 53: 643-650.
21. May DG, Ams PA, Richards WO, et al. The disposition of dapsone in cirrhosis. Clin Phannacol Tlier 1992; 51: 689-700.
22. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Phannacol Tlier 1990; 48: 619-627.
23. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the 'Pittsburgh Cocktail' approach to assess selective regulation of drug metabolizing enzymes. CHn Phannacol Tlier 1997; 62: 365-376.
24. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Phannacol Tlier 1984; 36: 773-780.
25. Yue QY, Hassleström J, Svensson JO,Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. BrJ Clin Pliannacol 1991; 31: 635-642.
26. Chen ZR, Somogyi AA, Reynolds G, Dochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. BrJ Clin Pliannacol 1991; 31: 381-390.
27. Otton SV, Schädel M, Cheung SW, Kaplan HL, Busto UE, Seilers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Phannacol Tlier 1993; 54: 463-472.
28. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmac Tlier 1990; 46: 377-394.